Market Overview

Global Anti-VEGF Antibodies Market to 2022: Roche, Novartis, Sanofi, Regeneron, Bayer & AstraZeneca Dominate the $100 Billion Market

Share:

Dublin, Aug. 09, 2018 (GLOBE NEWSWIRE) -- The "Anti-VEGF Antibodies: Global Technology Assessment, Market Analysis and Future Growth Trends" report has been added to ResearchAndMarkets.com's offering.

Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turnout to be fastest growing group of biotechnology-derived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017 and is forecast to grow at a double digit Compound Annual Growth Rate (CAGR) by year 2023.

Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, but the use of mAbs against VEGF have been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous potential in near future.

The report includes following key insights:

  • In this report we discuss the novel technologies/methodologies used for production, purification, structural modifications and formulation of mAbs against VEGF ligands in various human pathologies using technology distribution based on IP analysis
  • The report highlights the significant trends in efficacy, limitations and patient survival rate anti-VEGF antibodies therapy based on data available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and hPV19
  • This report showcases the competitive benchmarking of key industrial players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in development of anti-VEGF antibodies from laboratory to clinical trials
  • Product search and market forecast for trends in anti-VEGF mAbs will be extensively described
  • The report will further include detailed description of anti-VEGF antibodies in clinical trials and their beneficial effects on targeted patients especially cancer and age related macular degradation, autoimmune diseases
  • Report includes driving factors influencing global anti-VEGF mAbs market for year 2017-2022
  • Detailed description of SWOT and PEST analysis in development of anti-VEGF antibody therapy.

Key industry players

  • Roche
  • Novartis
  • Sanofi
  • Regeneron
  • Bayer
  • AstraZeneca

Key Topics Covered:

1. Technology Overview
1.1. List of Tables
1.2. List of Figures
1.3. Introduction
1.4. Objective & Scope
1.5. Research Methodology

2. Anti-VEGF antibodies: Technology Segmentation
2.1. Technology distributions
2.1.1. Anti-VEGF antibody sequences
2.1.1.1. Nucleotide sequences
2.1.1.2. Amino acid sequences
2.1.2. Anti-VEGF antibody expression systems
2.1.2.1. Prokaryotic expression vectors systems
2.2.2.2. Eukaryotic expression vectors systems
2.1.3. Anti-VEGF antibody production host cells/organisms
2.1.3.1. E. coli as host for antibody production
2.1.3.2. Yeast as host for antibody production
2.1.3.3. CHO cells as host for antibody production
2.1.3.4. Any other host system for antibody production
2.1.4. Anti-VEGF antibody host culture medium
2.1.4.1. Prokaryotic culture medium specific composition
2.1.4.2. Eukaryotic Culture medium specific composition
2.1.5. Anti-VEGF antibody purification methods
2.1.5.1. Affinity chromatography
2.1.5.2. Hydrophobic interaction chromatography
2.1.5.3. Ion exchange column chromatography
2.1.5.3.1. Anion exchange chromatography
2.1.5.3.2. Cation exchange chromatography
2.1.5.4. High performance-size exclusion chromatography
2.1.5.5. Any other methods for purification
2.1.6. Anti-VEGF nucleotides delivery to target site
2.1.6.1. Viral vectors for targeted delivery
2.1.6.1.1. Adenovirus
2.1.6.1.2. Adeno-associated virus (AAV)
2.1.6.1.3. Lentivirus
2.1.6.1.2. Virus-like particles (VLPs)
2.1.6.2. Any other vector system used
2.2. Anti-VEGF antibodies in clinical trials/approved by FDA/EMA
2.2.1. Bevacizumab/Avastin
2.2.2. Ranibizumab/Lucentis
2.2.3. Aflibercept/Eylea
2.2.4. Vanucizumab
2.2.5. Brolucizumab
2.2.6. hPV19
2.2.7. VGX-100
2.2.8. Sevacizumab
2.2.9. HuMV833

3. Anti-VEGF antibodies: Global IP Trends
3.1. Geographic Activity
3.1.1. United States
3.1.1.1 Top players in United States
3.1.1.2 Important IPs in United States
3.1.2. Europe
3.1.2.1 Top players in Europe
3.1.2.2 Important IPs in Europe
3.1.3. Asia
3.1.3.1 Top players in Asia
3.1.3.2 Important IPs in Asia
3.2. Technology Breakdown- Distribution of Anti-VEGF antibodies
3.2.1. IP claiming Sequences for anti-VEGF antibodies
3.2.2. IP claiming expression systems for anti-VEGF antibodies
3.2.3. IP claiming host cells/organisms for production of anti-VEGF antibodies
3.2.4 IP claiming methods for production and purifications
3.2.5. IP claiming delivery vectors for anti-VEGF antibodies
3.3. Competitive Intelligence: Anti-VEGF antibodies
3.3.1. Technology distribution and comparison between key players including research institutes/universities/industry
3.3.1. Sequence-based comparison of key players
3.3.2. Expression vector-based comparison of key players
3.3.3. Host cells/organisms-based comparison of key players
3.3.4. Culture medium composition-based comparison of key players
3.3.5. Targeted delivery system-based comparison of key players
3.3.6. Purification methodology-based comparison of key players
3.4. Collaborations/Acquisitions/Licensing Activity of key players in Anti-VEGF antibodies:
3.4.1. Collaboration between companies
3.4.2. Collaboration between company and universities
3.4.3. Licensing activity among universities, companies and individuals
3.4.4. Acquisition in the Anti-VEGF antibodies technology domain

4. Anti-VEGF antibodies: Different diseases targeted
4.1. Anti-VEGF antibody therapy for cancer
4.1.1. Anti-VEGF antibody therapy for colorectal cancer
4.1.2. Anti-VEGF antibody therapy for glioblastoma
4.1.3. Anti-VEGF antibody therapy for breast cancer
4.1.4. Anti-VEGF antibody therapy for renal carcinoma
4.1.5. Anti-VEGF antibody therapy for metastatic lung tumors
4.1.6. Anti-VEGF antibody therapy for any other cancer
4.2. Anti-VEGF antibody therapy for retinopathy
4.2.1. Anti-VEGF antibody therapy for age-related macular degeneration
4.2.2. Anti-VEGF antibody therapy for macular edema
4.2.3. Anti-VEGF antibody therapy for diabetic macular edema (DME)
4.2.4. Anti-VEGF antibody therapy for diabetic retinopathy (DR)
4.2.5. Anti-VEGF antibody therapy for myopic choroidal neovascularization
4.3. Anti-VEGF antibody therapy for any other disease related to VEGF overexpression/reduced expression

5. Anti-VEGF antibody: White Space Analysis

6. Recent activities in development of anti-VEGF antibody
6.1 Contract/funding information
6.1.1. Contract/funding objective
6.1.2. Contract/funding receiving company information
6.2. Partnership/Collaboration/Licensing
6.2.1. Partnership/Collaboration/Licensing objective
6.2.2. Information of associated companies
6.3. New emerging technologies
6.3.1. Information of associated company
6.3.2. Information of associated inventors
6.4. Undergoing research activities
6.4.1. Information of associated company
6.4.2. Information of associated inventors

7. Anti-VEGF Antibody Technology Opinions from Experts

8. Anti-VEGF Antibody Technology Collaboration Insights

9. Strategies of Companies involved in development of Anti-VEGF antibody

10. Recent Anti-VEGF Antibody Product Developments
10.1. Product overview
10.2. Company information

11. Global Trends Anti-VEGF Antibody Market
12.1. North America
12.2. South America
12.3. Europe
12.4. Asia-Pacific

12. Global Anti-VEGF antibody development: Top Industrial Players
12.1. Roche
12.2. Novartis
12.3. Sanofi
12.4. Regeneron
12.5. Bayer
12.6. AbbVie
12.7. Zymeworks
12.8. Elan Pharma
19.9. Five Prime Therapeutics
12.10. Kymab Ltd
12.11. Pfizer
12.12. AstraZeneca
12.13. Boehringer Ingelheim

13. Anti-VEGF Antibody - Market Determinants

14. Anti-VEGF Antibody -Opportunity Vs. Restraints

15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST

16. Anti-VEGF Antibody Market Development (2017-2022)

17. Conclusion

For more information about this report visit https://www.researchandmarkets.com/research/3dhwqw/global_antivegf?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Immune Disorders Drugs

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
ETTXWedbushInitiates Coverage On19.0
WINGWedbushDowngrades0.0
BMYCitigroupDowngrades57.0
INTCNomuraUpgrades0.0
HRZNKeefe Bruyette & WoodsDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.